FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 353:1591-1603 October 13, 2005 Number 15 Next

	Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

	Full Text PDF PDA Full Text Purchase this article Letters Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited E-mail When Letters Appear PubMed Citation

Malignant mesothelioma is an aggressive tumor of serosal surfaces, such as the pleura and the peritoneum.¹ This tumor was once rare, but its incidence is increasing worldwide, probably as a result of widespread exposure to asbestos, a factor with which it is associated (Table 1).⁸ There is substantial interest in this disease on the part of the medical community and the general public, because millions of people have been exposed to asbestos fibers, and many articles about the dangers of asbestos have appeared in the press.

View this table: [in this window] [in a new window]   Table 1. Worldwide Trends in the Epidemiologic Features of Malignant Mesothelioma.

 
In addition to . . . [Full Text of this Article]

Clinical Features

Causes

Epidemiologic Features

Pathogenesis

Biology

            Growth Advantage

            Immortalization by the Action of Telomerase

            Absence of Tumor-Suppressor Genes

            Induction of Antiapoptotic Processes

            Increased Angiogenesis

            Matrix Interactions

Advances in Diagnosis

Cytologic Analysis

Histopathological Analysis

Imaging

Serum Markers

Other Blood Tests

Pulmonary-Function Tests

DNA Microarray Studies

Prognostic Factors and Staging

Advances in Treatment

Surgery

Chemotherapy

Radiotherapy

Immunotherapy

Gene Therapy

Other Therapies

Palliation

Conclusions

Source Information

From the School of Medicine and Pharmacology (B.W.S.R., R.A.L.), the Department of Respiratory Medicine (B.W.S.R.), and the Western Australian Institute for Medical Research (B.W.S.R., R.A.L.), Sir Charles Gairdner Hospital, Nedlands, Perth, Australia.

Address reprint requests to Dr. Robinson at the School of Medicine and Pharmacology, 4th Fl., G Block, Sir Charles Gairdner Hospital, University of Western Australia, Nedlands, Perth 6009, Australia, or at bwsrobin@cyllene.uwa.edu.au.

Related Letters:

Malignant Mesothelioma
Pantanowitz L., Otis C. N., Muñoz A., Barceló R., López-Vivanco G., López-Ríos F., Ladanyi M., Robinson B. W.S., Lake R. A.
Extract | Full Text | PDF  
N Engl J Med 2006; 354:305-307, Jan 19, 2006. Correspondence

This article has been cited by other articles:

• Fukazawa, T., Matsuoka, J., Naomoto, Y., Maeda, Y., Durbin, M. L., Tanaka, N. (2008). Malignant Pleural Mesothelioma-Targeted CREBBP/EP300 Inhibitory Protein 1 Promoter System for Gene Therapy and Virotherapy. Cancer Res. 68: 7120-7129 [Abstract] [Full Text]  
• Christensen, B. C., Godleski, J. J., Marsit, C. J., Houseman, E. A., Lopez-Fagundo, C. Y., Longacker, J. L., Bueno, R., Sugarbaker, D. J., Nelson, H. H., Kelsey, K. T. (2008). Asbestos exposure predicts cell cycle control gene promoter methylation in pleural mesothelioma. Carcinogenesis 29: 1555-1559 [Abstract] [Full Text]  
• van Sandick, J. W., Kappers, I., Baas, P., Haas, R. L., Klomp, H. M. (2008). Surgical Treatment in the Management of Malignant Pleural Mesothelioma: A Single Institution's Experience. Ann. Surg. Oncol. 15: 1757-1764 [Abstract] [Full Text]  
• Watson, P. M., Miller, S. W., Fraig, M., Cole, D. J., Watson, D. K., Boylan, A. M. (2008). CaSm (LSm-1) Overexpression in Lung Cancer and Mesothelioma Is Required for Transformed Phenotypes. Am. J. Respir. Cell Mol. Bio. 38: 671-678 [Abstract] [Full Text]  
• Jeong, Y. J., Kim, S., Kwak, S. W., Lee, N. K., Lee, J. W., Kim, K.-I., Choi, K. U., Jeon, T. Y. (2008). Neoplastic and Nonneoplastic Conditions of Serosal Membrane Origin: CT Findings. RadioGraphics 28: 801-818 [Abstract] [Full Text]  
• de Perrot, M., McRae, K., Anraku, M., Karkouti, K., Waddell, T. K., Pierre, A. F., Darling, G., Keshavjee, S., Johnston, M. R. (2008). Risk Factors for Major Complications After Extrapleural Pneumonectomy for Malignant Pleural Mesothelioma. Ann. Thorac. Surg. 85: 1206-1210 [Abstract] [Full Text]  
• Kothmaier, H, Quehenberger, F, Halbwedl, I, Morbini, P, Demirag, F, Zeren, H, Comin, C E, Murer, B, Cagle, P T, Attanoos, R, Gibbs, A R, Galateau-Salle, F, Popper, H H (2008). EGFR and PDGFR differentially promote growth in malignant epithelioid mesothelioma of short and long term survivors. Thorax 63: 345-351 [Abstract] [Full Text]  
• Ramos-Nino, M. E., Blumen, S. R., Sabo-Attwood, T., Pass, H., Carbone, M., Testa, J. R., Altomare, D. A., Mossman, B. T. (2008). HGF Mediates Cell Proliferation of Human Mesothelioma Cells through a PI3K/MEK5/Fra-1 Pathway. Am. J. Respir. Cell Mol. Bio. 38: 209-217 [Abstract] [Full Text]  
• Dong, L.-F., Swettenham, E., Eliasson, J., Wang, X.-F., Gold, M., Medunic, Y., Stantic, M., Low, P., Prochazka, L., Witting, P. K., Turanek, J., Akporiaye, E. T., Ralph, S. J., Neuzil, J. (2007). Vitamin E Analogues Inhibit Angiogenesis by Selective Induction of Apoptosis in Proliferating Endothelial Cells: The Role of Oxidative Stress. Cancer Res. 67: 11906-11913 [Abstract] [Full Text]  
• Abayasiriwardana, K. S., Barbone, D., Kim, K.-U., Vivo, C., Lee, K. K., Dansen, T. B., Hunt, A. E., Evan, G. I., Broaddus, V. C. (2007). Malignant mesothelioma cells are rapidly sensitized to TRAIL-induced apoptosis by low-dose anisomycin via Bim. Molecular Cancer Therapeutics 6: 2766-2776 [Abstract] [Full Text]  
• Li, Q., Yano, S., Ogino, H., Wang, W., Uehara, H., Nishioka, Y., Sone, S. (2007). The Therapeutic Efficacy of Anti Vascular Endothelial Growth Factor Antibody, Bevacizumab, and Pemetrexed against Orthotopically Implanted Human Pleural Mesothelioma Cells in Severe Combined Immunodeficient Mice. Clin. Cancer Res. 13: 5918-5925 [Abstract] [Full Text]  
• Comar, M., Rizzardi, C., de Zotti, R., Melato, M., Bovenzi, M., Butel, J. S., Campello, C. (2007). SV40 Multiple Tissue Infection and Asbestos Exposure in a Hyperendemic Area for Malignant Mesothelioma. Cancer Res. 67: 8456-8459 [Abstract] [Full Text]  
• Aung, W., Hasegawa, S., Furukawa, T., Saga, T. (2007). Potential role of ferritin heavy chain in oxidative stress and apoptosis in human mesothelial and mesothelioma cells: implications for asbestos-induced oncogenesis. Carcinogenesis 28: 2047-2052 [Abstract] [Full Text]  
• Andujar, P., Lecomte, C., Renier, A., Fleury-Feith, J., Kheuang, L., Daubriac, J., Janin, A., Jaurand, M.-C. (2007). Clinico-pathological features and somatic gene alterations in refractory ceramic fibre-induced murine mesothelioma reveal mineral fibre-induced mesothelioma identities. Carcinogenesis 28: 1599-1605 [Abstract] [Full Text]  
• Creaney, J., Yeoman, D., Naumoff, L. K, Hof, M., Segal, A., Musk, A. W., De Klerk, N., Horick, N., Skates, S. J, Robinson, B. W S (2007). Soluble mesothelin in effusions: a useful tool for the diagnosis of malignant mesothelioma. Thorax 62: 569-576 [Abstract] [Full Text]  
• Ceresoli, G. L., Gridelli, C., Santoro, A. (2007). Multidisciplinary Treatment of Malignant Pleural Mesothelioma. The Oncologist 12: 850-863 [Abstract] [Full Text]  
• Opitz, I., Lardinois, D., Arni, S., Hillinger, S., Vogt, P., Odermatt, B., Rousson, V., Weder, W. (2007). Local recurrence model of malignant pleural mesothelioma for investigation of intrapleural treatment. Eur. J. Cardiothorac. Surg. 31: 772-778 [Abstract] [Full Text]  
• Yan, T., Welch, L, Black, D, Sugarbaker, P. (2007). A systematic review on the efficacy of cytoreductive surgery combined with perioperative intraperitoneal chemotherapy for diffuse malignancy peritoneal mesothelioma. Ann Oncol 18: 827-834 [Abstract] [Full Text]  
• Pespeni, M. H., Hodnett, M., Abayasiriwardana, K. S., Roux, J., Howard, M., Broaddus, V. C., Pittet, J.-F. (2007). Sensitization of Mesothelioma Cells to Tumor Necrosis Factor-Related Apoptosis-Inducing Ligand-Induced Apoptosis by Heat Stress via the Inhibition of the 3-Phosphoinositide-Dependent Kinase 1/Akt Pathway. Cancer Res. 67: 2865-2871 [Abstract] [Full Text]  
• Takahashi, Y., Miyaki, K., Nakayama, T. (2007). Analysis of news of the Japanese asbestos panic: a supposedly resolved issue that turned out to be a time bomb. J Public Health (Oxf) 29: 62-69 [Abstract] [Full Text]  
• de Perrot, M., Uy, K., Anraku, M., Tsao, M. S., Darling, G., Waddell, T. K., Pierre, A. F., Bezjak, A., Keshavjee, S., Johnston, M. R. (2007). Impact of lymph node metastasis on outcome after extrapleural pneumonectomy for malignant pleural mesothelioma. J. Thorac. Cardiovasc. Surg. 133: 111-116 [Abstract] [Full Text]  
• Tyszko, S. M., Marano, G. D., Tallaksen, R. J., Gyure, K. A. (2007). Best Cases from the AFIP: Malignant Mesothelioma. RadioGraphics 27: 259-264 [Full Text]  
• Robinson, C., van Bruggen, I., Segal, A., Dunham, M., Sherwood, A., Koentgen, F., Robinson, B. W.S., Lake, R. A. (2006). A Novel SV40 TAg Transgenic Model of Asbestos-Induced Mesothelioma: Malignant Transformation Is Dose Dependent.. Cancer Res. 66: 10786-10794 [Abstract] [Full Text]  
• Ceresoli, G. L., Chiti, A., Zucali, P. A., Rodari, M., Lutman, R. F., Salamina, S., Incarbone, M., Alloisio, M., Santoro, A. (2006). Early Response Evaluation in Malignant Pleural Mesothelioma by Positron Emission Tomography With [18F]Fluorodeoxyglucose. JCO 24: 4587-4593 [Abstract] [Full Text]  
• Holloway, A. J., Diyagama, D. S., Opeskin, K., Creaney, J., Robinson, B. W.S., Lake, R. A., Bowtell, D. D.L. (2006). A Molecular Diagnostic Test for Distinguishing Lung Adenocarcinoma from Malignant Mesothelioma Using Cells Collected from Pleural Effusions. Clin. Cancer Res. 12: 5129-5135 [Abstract] [Full Text]  
• Flynn, J., Berg, R. W., Wong, T., van Aken, M., Vincent, M. D., Fukushima, M., Koropatnick, J. (2006). Therapeutic potential of antisense oligodeoxynucleotides to down-regulate thymidylate synthase in mesothelioma.. Molecular Cancer Therapeutics 5: 1423-1433 [Abstract] [Full Text]  
• Ceresoli, G. L., Zucali, P. A., Favaretto, A. G., Grossi, F., Bidoli, P., Del Conte, G., Ceribelli, A., Bearz, A., Morenghi, E., Cavina, R., Marangolo, M., Parra, H. J. S., Santoro, A. (2006). Phase II Study of Pemetrexed Plus Carboplatin in Malignant Pleural Mesothelioma. JCO 24: 1443-1448 [Abstract] [Full Text]  
• Schottenfeld, D., Beebe-Dimmer, J. (2006). Chronic inflammation: a common and important factor in the pathogenesis of neoplasia.. CA Cancer J Clin 56: 69-83 [Abstract] [Full Text]  
• Pantanowitz, L., Otis, C. N., Munoz, A., Barcelo, R., Lopez-Vivanco, G., Lopez-Rios, F., Ladanyi, M., Robinson, B. W.S., Lake, R. A. (2006). Malignant Mesothelioma. NEJM 354: 305-307 [Full Text]